Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Transform Wealth LLC

Transform Wealth LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,317 shares of the company's stock after buying an additional 6,014 shares during the period. Transform Wealth LLC's holdings in Novo Nordisk A/S were worth $8,199,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the third quarter worth approximately $28,000. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S in the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $48,000. Finally, M&R Capital Management Inc. raised its stake in shares of Novo Nordisk A/S by 260.5% during the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company's stock worth $49,000 after buying an additional 297 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE NVO traded up $1.99 during trading hours on Tuesday, hitting $80.68. 6,086,188 shares of the company's stock traded hands, compared to its average volume of 9,007,828. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm's 50-day moving average is $97.15 and its 200-day moving average is $116.47. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a market capitalization of $362.07 billion, a PE ratio of 26.10, a PEG ratio of 0.84 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on NVO shares. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of "Buy" and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.